Stryker completes acquisition of MOLLI Surgical

31st July, 2024

Advancing surgical solutions in breast cancer care

image credit- shutterstock

image credit- shutterstock

Stryker announced that it has completed the acquisition of MOLLI Surgical Inc., a privately held company specializing in the development of wire-free soft tissue localization technology for breast conserving surgery. MOLLI's portfolio further strengthens Stryker's surgical solutions in breast cancer care.

The MOLLI 2 localization system is designed for ease of use and reliability to support a more efficient surgical workflow. The MOLLI Marker is the smallest on the market at 3.2 mm and is detectable in dense breasts and through hematoma. The MOLLI 2 tablet provides surgeons with four real-time types of feedback: distance, visual, auditory and 3D directional guidance.

Andrés Rosales, vice president and general manager of Stryker's Endoscopy business said, "The acquisition of MOLLI Surgical represents a significant step forward in our goal to provide surgeons with the most advanced tools to improve patient care. MOLLI Surgical complements our existing portfolio in the breast cancer space, which includes our SPY fluorescence imaging technology for lymphatic mapping and lighted retractors."

 

© 2023 MM Activ Sci-Tech Communications. All rights reserved | Disclaimer